The Gastrointestinal Market Outlook to 2012

As the GIT Market begins to feature increasingly high levels of generic competition, the focus of pharmaceutical R&D strategies has shifted towards new therapy areas such as Crohn’s disease and Irritable Bowel Syndrome (IBS). Although such shifts are becoming the driving force for market transformation, growth rates may remain low due to the increased availability of effective generic medicines and fewer launches of innovative new drugs. ‘The Gastrointestinal Market Outlook to 2012’ is a new report published by Business Insights that provides a detailed epidemiological analysis of key indications within major GIT markets, and examines the factors impacting their prevalence. The dynamics of the market are examined through an analysis of leading brands within each indication and a profile of the pharma companies and market trends influencing the sales of GIT treatments. Forecasts for major product sales over the 2006-12 period are also provided.

About the Author: Melissa Zebrowski

Melissa Zebrowski is a pharmaceutical industry analyst with over seven years’ of experience in healthcare and biopharma policy. During this time she has worked for four years as a consultant providing market research and analysis services, with a therapeutic focus spanning Oncology, Central Nervous System, Gastrointestinal, and

Infectious Disease areas.

Published: October 2007 - Global.
Table of Contents
Table of Contents (PDF)
Price: $2,875.00 / GBP1,437.50